Treatment of COVID-19: a review of current and prospective pharmacotherapies

• Published in: British journal of hospital medicine (London, England : 2005) Vol. 82; no. 3; p. 1
• Main Authors: Quek, Eleanor, Tahir, Hasan, Kumar, Poornima, Hastings, Robert, Jha, Rajeev
• Format: Journal Article
• Language: English
• Published: England 02.03.2021
• Subjects: Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Alanine - analogs & derivatives; Alanine - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Anticoagulants - therapeutic use; Antiviral Agents - therapeutic use; Azetidines - therapeutic use; Colchicine - therapeutic use; COVID-19 - drug therapy; COVID-19 - therapy; Dexamethasone - therapeutic use; Glucocorticoids - therapeutic use; Humans; Immunization, Passive; Immunologic Factors - therapeutic use; Ivermectin - therapeutic use; Janus Kinase Inhibitors - therapeutic use; Platelet Aggregation Inhibitors - therapeutic use; Purines - therapeutic use; Pyrazoles - therapeutic use; SARS-CoV-2; Sulfonamides - therapeutic use; COVID-19; Immunomodulator; Anticoagulation; Antivirals
• ISSN: 1750-8460
• DOI: 10.12968/hmed.2021.0112

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and have grave health and socioeconomic consequences worldwide. Researchers have raced to understand the pathophysiological mechanisms underpinning the disease caused by SARS-CoV-2 so that effective therapeutic targets can be discovered. This review summarises the key pharmacotherapies that are being investigated for treatment of COVID-19, including antiviral, immunomodulator and anticoagulation strategies.